Literature DB >> 20506261

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).

Ali S Murad1, Liz Down, George Davey Smith, Jenny L Donovan, Janet Athene Lane, Freddie C Hamdy, David E Neal, Richard M Martin.   

Abstract

Evidence from laboratory studies suggests that chronic inflammation plays an important role in prostate cancer aetiology. This has resulted in speculation that nonsteroidal anti-inflammatory drugs may protect against prostate cancer development. We analysed data from a cross-sectional case-control study (n(cases) = 1,016; n(controls) = 5,043), nested within a UK-wide population-based study that used prostate specific antigen (PSA) testing for identification of asymptomatic prostate cancers, to investigate the relationship of aspirin, nonsteroidal anti-inflammatory drug (NSAID) and paracetamol use with prostate cancer. In conditional logistic regression models accounting for stratum matching on age (5-year age bands) and recruitment centre, use of non-aspirin NSAIDs [odds ratio (OR) = 1.32; 95% confidence interval (CI): 1.04-1.67] or all NSAIDs (OR = 1.25; 95% CI = 1.07-1.47) were positively associated with prostate cancer. There were weaker, not conventionally statistically significant, positive associations of aspirin (OR = 1.13; 95% CI = 0.94-1.36) and paracetamol (OR = 1.20; 95% CI = 0.90-1.60) with prostate cancer. Mutual adjustment for aspirin, non-aspirin NSAIDs or paracetamol made little difference to these results. There was no evidence of confounding by age, family history of prostate cancer, body mass index or self-reported diabetes. Aspirin, NSAID and paracetamol use were associated with reduced serum PSA concentrations amongst controls. Our findings do not support the hypothesis that NSAIDs reduce the risk of PSA-detected prostate cancer. Our conclusions are unlikely to be influenced by PSA detection bias because the inverse associations of aspirin, NSAID and paracetamol use with serum PSA would have attenuated (not generated) the observed positive associations.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20506261     DOI: 10.1002/ijc.25465

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Prostate cancer: The mire of modifiable risk factors.

Authors:  Rebecca Drake
Journal:  Nat Rev Urol       Date:  2010-07       Impact factor: 14.432

2.  Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies.

Authors:  Tian-Bao Huang; Yang Yan; Zhui-Feng Guo; Xiao-Long Zhang; Huan Liu; Jiang Geng; Xu-Dong Yao; Jun-Hua Zheng
Journal:  Int Urol Nephrol       Date:  2014-04-01       Impact factor: 2.370

Review 3.  Aspirin and urologic cancer risk: an update.

Authors:  Cristina Bosetti; Valentina Rosato; Silvano Gallus; Carlo La Vecchia
Journal:  Nat Rev Urol       Date:  2012-01-24       Impact factor: 14.432

4.  Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.

Authors:  Adriana C Vidal; Lauren E Howard; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Stephen J Freedland
Journal:  Clin Cancer Res       Date:  2014-12-17       Impact factor: 12.531

5.  Metabolic imbalance and prostate cancer progression.

Authors:  Anya J Burton; Kate M Tilling; Jeff M Holly; Freddie C Hamdy; Mari-Anne E Rowlands; Jenny L Donovan; Richard M Martin
Journal:  Int J Mol Epidemiol Genet       Date:  2010-07-25

6.  Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.

Authors:  J L Wright; L Chéry; S Holt; D W Lin; M Luedeke; A E Rinckleb; C Maier; J L Stanford
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-27       Impact factor: 5.554

7.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

8.  Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.

Authors:  Louise K Mercer; Rebecca Davies; James B Galloway; Audrey Low; Mark Lunt; William G Dixon; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2013-01       Impact factor: 7.580

9.  Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study.

Authors:  F M Shebl; L C Sakoda; A Black; J Koshiol; G L Andriole; R Grubb; T R Church; D Chia; C Zhou; L W Chu; W-Y Huang; U Peters; V A Kirsh; N Chatterjee; M F Leitzmann; R B Hayes; A W Hsing
Journal:  Br J Cancer       Date:  2012-06-21       Impact factor: 7.640

10.  Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells.

Authors:  Kazuhiro Iguchi; Maki Hashimoto; Masafumi Kubota; Shuji Yamashita; Mitsuhiro Nakamura; Shigeyuki Usui; Tadashi Sugiyama; Kazuyuki Hirano
Journal:  Oncol Lett       Date:  2014-03-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.